vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $124.5M, roughly 1.5× PagerDuty, Inc.). PagerDuty, Inc. runs the higher net margin — 129.7% vs 0.9%, a 128.8% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 4.7%). PagerDuty, Inc. produced more free cash flow last quarter ($24.1M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 5.9%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
FOLD vs PD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $124.5M |
| Net Profit | $1.7M | $161.6M |
| Gross Margin | 85.7% | 85.3% |
| Operating Margin | 8.6% | 6.5% |
| Net Margin | 0.9% | 129.7% |
| Revenue YoY | 23.7% | 4.7% |
| Net Profit YoY | -88.5% | 2827.7% |
| EPS (diluted) | $0.00 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $185.2M | $124.5M | ||
| Q3 25 | $169.1M | $123.4M | ||
| Q2 25 | $154.7M | $119.8M | ||
| Q1 25 | $125.2M | $121.4M | ||
| Q4 24 | $149.7M | $118.9M | ||
| Q3 24 | $141.5M | $115.9M | ||
| Q2 24 | $126.7M | $111.2M | ||
| Q1 24 | $110.4M | $111.1M |
| Q4 25 | $1.7M | $161.6M | ||
| Q3 25 | $17.3M | $9.6M | ||
| Q2 25 | $-24.4M | $-7.2M | ||
| Q1 25 | $-21.7M | $-8.8M | ||
| Q4 24 | $14.7M | $-5.9M | ||
| Q3 24 | $-6.7M | $-10.9M | ||
| Q2 24 | $-15.7M | $-17.1M | ||
| Q1 24 | $-48.4M | $-28.2M |
| Q4 25 | 85.7% | 85.3% | ||
| Q3 25 | 88.5% | 84.6% | ||
| Q2 25 | 90.2% | 84.0% | ||
| Q1 25 | 90.7% | 83.6% | ||
| Q4 24 | 90.1% | 83.0% | ||
| Q3 24 | 90.6% | 82.7% | ||
| Q2 24 | 91.1% | 82.6% | ||
| Q1 24 | 87.7% | 81.7% |
| Q4 25 | 8.6% | 6.5% | ||
| Q3 25 | 20.3% | 2.9% | ||
| Q2 25 | -6.1% | -8.6% | ||
| Q1 25 | -6.3% | -9.6% | ||
| Q4 24 | 10.7% | -8.7% | ||
| Q3 24 | 15.3% | -13.8% | ||
| Q2 24 | 11.8% | -19.5% | ||
| Q1 24 | -25.1% | -30.1% |
| Q4 25 | 0.9% | 129.7% | ||
| Q3 25 | 10.2% | 7.8% | ||
| Q2 25 | -15.8% | -6.0% | ||
| Q1 25 | -17.3% | -7.2% | ||
| Q4 24 | 9.8% | -5.0% | ||
| Q3 24 | -4.8% | -9.4% | ||
| Q2 24 | -12.4% | -15.4% | ||
| Q1 24 | -43.9% | -25.3% |
| Q4 25 | $0.00 | $1.69 | ||
| Q3 25 | $0.06 | $0.10 | ||
| Q2 25 | $-0.08 | $-0.07 | ||
| Q1 25 | $-0.07 | $-0.12 | ||
| Q4 24 | $0.05 | $-0.07 | ||
| Q3 24 | $-0.02 | $-0.14 | ||
| Q2 24 | $-0.05 | $-0.26 | ||
| Q1 24 | $-0.16 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $547.8M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $320.5M |
| Total Assets | $949.9M | $1.0B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $293.5M | $547.8M | ||
| Q3 25 | $263.8M | $567.9M | ||
| Q2 25 | $231.0M | $597.1M | ||
| Q1 25 | $250.6M | $570.8M | ||
| Q4 24 | $249.9M | $542.2M | ||
| Q3 24 | $249.8M | $599.3M | ||
| Q2 24 | $260.1M | $592.8M | ||
| Q1 24 | $239.6M | $571.2M |
| Q4 25 | $392.7M | — | ||
| Q3 25 | $392.0M | — | ||
| Q2 25 | $391.3M | — | ||
| Q1 25 | $390.7M | $484.5M | ||
| Q4 24 | $390.1M | — | ||
| Q3 24 | $389.5M | — | ||
| Q2 24 | $388.9M | — | ||
| Q1 24 | $388.4M | $489.5M |
| Q4 25 | $274.2M | $320.5M | ||
| Q3 25 | $230.4M | $180.7M | ||
| Q2 25 | $204.3M | $145.7M | ||
| Q1 25 | $193.6M | $129.8M | ||
| Q4 24 | $194.0M | $111.6M | ||
| Q3 24 | $178.8M | $164.7M | ||
| Q2 24 | $132.5M | $174.0M | ||
| Q1 24 | $130.7M | $171.6M |
| Q4 25 | $949.9M | $1.0B | ||
| Q3 25 | $868.8M | $891.5M | ||
| Q2 25 | $815.3M | $926.8M | ||
| Q1 25 | $789.8M | $927.3M | ||
| Q4 24 | $785.0M | $866.8M | ||
| Q3 24 | $786.6M | $916.0M | ||
| Q2 24 | $749.5M | $924.0M | ||
| Q1 24 | $721.8M | $925.3M |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.02× | 3.73× | ||
| Q4 24 | 2.01× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 2.93× | — | ||
| Q1 24 | 2.97× | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $24.8M |
| Free Cash FlowOCF − Capex | $16.0M | $24.1M |
| FCF MarginFCF / Revenue | 8.6% | 19.3% |
| Capex IntensityCapex / Revenue | 0.2% | 0.6% |
| Cash ConversionOCF / Net Profit | 9.62× | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $24.8M | ||
| Q3 25 | $35.7M | $34.0M | ||
| Q2 25 | $-26.5M | $30.7M | ||
| Q1 25 | $7.8M | $31.4M | ||
| Q4 24 | $-3.9M | $22.1M | ||
| Q3 24 | $-23.0M | $35.8M | ||
| Q2 24 | $22.7M | $28.6M | ||
| Q1 24 | $-29.7M | $22.2M |
| Q4 25 | $16.0M | $24.1M | ||
| Q3 25 | $35.3M | $33.1M | ||
| Q2 25 | $-28.9M | $30.2M | ||
| Q1 25 | $7.5M | $30.3M | ||
| Q4 24 | $-4.2M | $21.5M | ||
| Q3 24 | $-23.3M | $35.1M | ||
| Q2 24 | $21.6M | $28.2M | ||
| Q1 24 | $-31.5M | $21.2M |
| Q4 25 | 8.6% | 19.3% | ||
| Q3 25 | 20.9% | 26.8% | ||
| Q2 25 | -18.7% | 25.2% | ||
| Q1 25 | 6.0% | 24.9% | ||
| Q4 24 | -2.8% | 18.1% | ||
| Q3 24 | -16.5% | 30.3% | ||
| Q2 24 | 17.0% | 25.4% | ||
| Q1 24 | -28.5% | 19.1% |
| Q4 25 | 0.2% | 0.6% | ||
| Q3 25 | 0.2% | 0.7% | ||
| Q2 25 | 1.6% | 0.4% | ||
| Q1 25 | 0.2% | 0.9% | ||
| Q4 24 | 0.2% | 0.5% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.9% | 0.4% | ||
| Q1 24 | 1.6% | 0.9% |
| Q4 25 | 9.62× | 0.15× | ||
| Q3 25 | 2.06× | 3.55× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.27× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
